Our results indicated that SOCS5/JAK2/STAT3 was involved in anti-leukemia process of leonurine and that SOCS5 may be a potential diagnostic marker and therapeutic target for CML. This evidence concerns the gene SOCS5 and chronic myelogenous leukemia, BCR-ABL1 positive.